COVID-19 trials registries data warehouse

https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12175

Hend;Doaa Ibrahim;Nagy

hend.dr@gmail.com; doaahabiba123@gmail.com

2020-06-30

Not recruiting

RCT

Randomized

Parallel

Blind label

multi-center

Prevention

? Age 18-80 years old ? Subjects who are willing to comply with the requirements of the study protocol and scheduled visits (for example, completion of the subject diary, return for follow-up visits) and who are willing to make themselves available for the duration of the study with access to a consistent means of telephone contact,

? Acute severe illness ? Recent receipt of a blood product ? History of thrombocytopenia ? Pregnant females ? Any chronic medical condition ? Any participant receiving any immune suppressive medication ? Immunocompromised staff ? Participants who have egg allergy ? Participants who care for immune compromised hosts at home ? Participants who had documented COVID-19 either by RT-PCR or radiologically in the past six months

2

Dar Al Fouad Hospital

18

80

Egypt

Health workers

N/A

200

1. COVID-19 incidence [ Time Frame: Measured over the 6 months following randomization]2. Number of participants with asymptomatic or mild COVID-19 disease defined asI. fever (using a self-reported questionnaire); plusII. at least one sign or symptom of respiratory disease including cough; runny/blocked nose (using self-reported questionnaire); plusIII. positive SARS-Cov-2 test (PCR or serology)

| Declared number of arm (2.0) differs from found arms (3.0)

Phase 3

[{"arm_notes": "1", "treatment_id": 774, "treatment_name": "Measles mumps rubella vaccine", "treatment_type": "Non covid vaccine", "pharmacological_treatment": "Non covid vaccine"}, {"arm_notes": "1", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]